Potentia Pharmaceuticals, Inc.

14 articles about Potentia Pharmaceuticals, Inc.

• Apellis Pharmaceuticals To Acquire Potentia Pharmaceuticals, Inc.

  11/20/2014

• Potentia Pharmaceuticals, Inc. Enters into Licensing and Purchase Option Agreements with Alcon Laboratories, Inc.; Deal Provides Path for Alcon to Acquire Potentia

  10/23/2009

• Potentia Pharmaceuticals, Inc.'s POT-4 Drug Candidate for Age-Related Macular Degeneration Successfully Completes Phase I Clinical Trial - Prepares for Phase II

  5/4/2009

• Potentia Pharmaceuticals, Inc. Appoints Johanna M. Seddon, M.D. and Janet Stoltz Sunness, M.D. to Scientific Advisory Board

  11/11/2008

• Potentia Pharmaceuticals, Inc.' Drug Candidate for Age-Related Macular Degeneration Shows Positive Safety Profile in Phase I Clinical Trial AMD Patients Treated with POT-4 Demonstrate No Adverse Toxic Effects

  11/10/2008

• Potentia Pharmaceuticals, Inc. to Present ASaP Phase I Clinical Trial Data for POT-4 at the American Academy of Ophthalmology Annual Meeting

  10/27/2008

• Potentia Pharmaceuticals, Inc. Announces Positive Safety Data and Study Expansion in Phase I Trial for Lead Drug Candidate POT-4

  9/29/2008

• Potentia Pharmaceuticals, Inc. Secures Additional $12 Million in Funding

  4/9/2008

• Potentia Pharmaceuticals, Inc. Announces Initiation of Phase I Clinical Trials to Evaluate its Lead Compound for Age-Related Macular Degeneration

  3/20/2007

• Potentia Pharmaceuticals, Inc. Raises $5 Million from Private Investors

  3/8/2007

• Zyentia Ltd Announces Research Collaboration With Potentia Pharmaceuticals, Inc.

  1/8/2007

• Potentia Pharmaceuticals, Inc. Appoints Armen H. Tashjian, Jr., M.D. To Its Scientific Advisory Board

  12/6/2006

• Potentia Pharmaceuticals, Inc. Licenses Complement Inhibitor From The University of Pennsylvania

  8/8/2006

• Omnia Biologics, Inc. And Potentia Pharmaceuticals, Inc. Sign Manufacturing Agreement

  8/8/2006